targeted Therapies
With no Compromise
With no Compromise
PDC Therapeutics is a clinical-stage biotechnology start-up developing smart nanomedicines for targeted therapies.
Superior Therapeutic Index
Sagitta® biodegradable conjugation platforms are discovered to reinforce ideal performances in terms of the therapeutic index, pharmacokinetics and manufacturability.
targeted Therapies With no Compromise
PDC Therapeutics is a clinical-stage biotechnology start-up developing smart nanomedicines for targeted therapies.
Superior Therapeutic Index
Sagitta® biodegradable conjugation platforms are discovered to reinforce ideal performances in terms of the therapeutic index, pharmacokinetics and manufacturability.
Phase 1 study of RS-0139 is now part of the ESMO Congress 2026 scientific programme
The ESMO Congress will be held in Madrid at 23-27 October 2026. “First-in-human phase Ia/Ib study…
PDC Therapeutics Co-Founder Prof. Rana Sanyal won the European Prize for Women Innovators
PDC Therapeutics Co‑Founder Prof. Rana Sanyal wins the European Women Innovators Award
Building better docetaxel therapy with nanocarrier technology, covered by BioWorld
PDC Therapeutics SA has passed the first test of its novel nanocarrier technology…
